Cardiac myosin binding protein-C: A potential early-stage, cardiac-specific biomarker of ischemia-reperfusion injury

Biomarkers in Medicine

Volumn 6, Issue 1, 2012, Pages 69-72

  Sadayappan, Sakthivel ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

cardiac biomarker; cardiac myosin binding protein C; cardiac troponin I; Meso Scale Discovery; myocardial infarction; selective reaction monitoring

Indexed keywords

BIOLOGICAL MARKER; MYOSIN BINDING PROTEIN C; TROPONIN T;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SEVERITY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; MYOSIN BINDING PROTEIN C GENE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PERICARDITIS; PREDICTIVE VALUE; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PROCESSING; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; CARRIER PROTEINS; HUMANS; MYOCARDIUM; ORGAN SPECIFICITY; REPERFUSION INJURY; TIME FACTORS;

EID: 84856606810     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.100     Document Type: Review

References (25)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123(4), e18-e209 (2011).
2. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation 117(2), 296-329 (2008).
3. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am. J. Med. 124(1), 40-47 (2011).
4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7), e148-e304 (2007).
5. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123(18), 2022-2060 (2011).
6. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N. Engl. J. Med. 360(21), 2165-2175 (2009).
7. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 116(22), 2634-2653 (2007). (Pubitemid 350182388)
8. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N. Engl. J. Med. 361(9), 868-877 (2009).
9. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N. Engl. J. Med. 361(9), 858-867 (2009).
10. Govindan S, McElligott A, Muthusamy S, et al. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J. Mol. Cell Cardiol. 52(1), 154-164 (2011).
11. Sadayappan S, Gulick J, Osinska H, et al. Cardiac myosin binding protein-C phosphorylation and cardiac function. Circ. Res. 97(11), 1156-1163 (2005).
12. Sadayappan S, Robbins J. The death of transcriptional chauvinism in the control and regulation of cardiac contractility. Ann. NY Acad. Sci. 1123, 1-9 (2008). (Pubitemid 351431298)
13. Sadayappan S, Osinska H, Klevitsky R, et al. Cardiac myosin binding protein-C phosphorylation is cardioprotective. Proc. Natl Acad. Sci. USA 103(45), 16918-16923 (2006). (Pubitemid 44737353)
14. Sadayappan S, Gulick J, Klevitsky R, et al. Cardiac myosin binding protein-C phosphorylation in a {b}-myosin heavy chain background. Circulation 119(9), 1253-1262 (2009).
15. Sadayappan S, Gulick J, Osinska H, et al. A critical function for Ser-282 in cardiac myosin binding protein-C phosphorylation and cardiac function. Circ. Res. 109(2), 141-150 (2011).
16. Tong CW, Stelzer JE, Greaser ML, Powers PA, Moss RL. Acceleration of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ. Res. 103(9), 974-982 (2008).
17. Luther PK, Winkler H, Taylor K, et al. Direct visualization of myosin-binding protein C bridging myosin and actin filaments in intact muscle. Proc. Natl Acad. Sci. USA 108(28), 11423-11428 (2011).
18. Van Eyk JE. Overview: the maturing of proteomics in cardiovascular research. Circ. Res. 108(4), 490-498 (2011).
19. Meng Z, Veenstra TD. Targeted mass spectrometry approaches for protein biomarker verification. J. Proteomics 74(12), 2650-2659 (2011).
20. Sheng S, Skalnikova H, Meng A, et al. Intact protein separation by one- and two-dimensional liquid chromatography for the comparative proteomic separation of partitioned serum or plasma. Methods Mol. Biol. 728, 29-46 (2011).
21. Rodriguez H, Rivers R, Kinsinger C, et al. Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective. Proteomics Clin. Appl. 4(12), 904-914 (2010).
22. Fu Q, Schoenhoff FS, Savage WJ, Zhang P, Van Eyk JE. Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin. Appl. 4(3), 271-284 (2010).
23. Fu Q, Zhu J, Van Eyk JE. Comparison of multiplex immunoassay platforms. Clin. Chem. 56(2), 314-318 (2010).
24. Toyama A, Nakagawa H, Matsuda K, et al. Deglycosylation and label-free quantitative LC-MALDI MS applied to efficient serum biomarker discovery of lung cancer. Proteome Sci. 9, 18 (2011).
25. Van Den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(5-6), 590-602 (2010).